3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
42
Lymphoma, Follicular
31
Lymphoma, Mantle-Cell
22
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Large B-Cell, Diffuse
15
Lymphoma
13
Lymphoma, Non-Hodgkin
9
Lymphoma, B-Cell
8
Neoplasms
6
Leukemia, Hairy Cell
4
Leukemia, B-Cell
4
Neoplasm, Residual
3
Leukemia
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Disease
2
Dendritic Cell Sarcoma, Interdigitating
2
Burkitt Lymphoma
2
Mycosis Fungoides
1
Lymphoproliferative Disorders
1
Lymphoma, T-Cell, Cutaneous
1
Leukemia, Prolymphocytic, B-Cell
1
Indolent Non-Hodgkin's Lymphoma
1
Indolent Non-Hodgkin Lymphoma
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Breast Neoplasms
1
Anemia
1
Interventions
Rituximab
77
Cyclophosphamide
54
fludarabine phosphate
50
Peripheral Blood Stem Cell Transplantation
44
Mycophenolic Acid
34
Whole-Body Irradiation
33
Tacrolimus
25
Cyclosporine
23
Busulfan
22
Bortezomib
22
Dexamethasone
21
Etoposide
19
ibrutinib
18
Melphalan
17
Antilymphocyte Serum
17
Methotrexate
15
Lenalidomide
15
Filgrastim
14
Radiotherapy
12
Bendamustine Hydrochloride
12
Sirolimus
10
Calcium Dobesilate
10
Flow Cytometry
9
Everolimus
9
Cyclosporins
9
zanubrutinib
8
Alemtuzumab
7
ibritumomab tiuxetan
6
Transplantation
6
Therapeutics
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Waldenstrom Macroglobulinemia
×
obinutuzumab
×
Clear all
NCT02962401
2023-08-29
RemodelWM3
French Innovative Leukemia Organisation
Phase 2
Completed
50 enrolled
NCT03679455
2018-11-13
OBI-1
Polish Myeloma Consortium
Phase 2
Unknown
30 enrolled